IL1B and autoimmune disease: Moreover, IRF2 silencing significantly attenuated canonical and noncanonical inflammasome-mediated pyroptosis and IL-1β release (74), suggesting that IRF2 is a reliable drug target for the treatment of autoimmune disease.